stockguard Wednesday, 02/13/19 05:23:12 PM Re: None Post # of 14 Biotech Bonanza: The Mergers And Acquisitions Theme https://seekingalpha.com/article/4240702-biotech-bonanza-mergers-acquisitions-theme A recent analysis by EvaluatePharma revealed that based on the historical data over the past 5 years, a majority of the buyouts have occurred for products in the Pre-clinical and Phase II stages. The lower number of Phase III buyouts is understandable as such assets are also more scarce, besides being at a higher valuation, compared to the volume of assets available in Pre-clinical and Phase II. The analysis also indicated that the leading therapy area for buyouts remains Oncology, as it has been for many years. BBC Daily Chart insert-text-here